Management of physical health in patients with schizophrenia: Practical recommendations

European Psychiatry

Volumn 25, Issue SUPPL. 2, 2010, Pages

  Heald, A ^a   Montejo, A L ^b   Millar, H ^d   De Hert, M ^e   McCrae, J ^f   Correll, C U ^c  

^a LEIGHTON HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d NHS TAYSIDE   (United Kingdom)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f EUFAMI   (Belgium)

Author keywords

Antipsychotic Therapy; Cardiovascular Disease; Multidisciplinary Care; Physical Health; Practical Recommendations; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COORDINATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG INDICATION; ELECTRONIC SPREADSHEET; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HUMAN; HYPERPROLACTINEMIA; LIFESTYLE MODIFICATION; MENTAL DISEASE; METABOLIC DISORDER; PARAMETER; PATIENT CARE; PHYSICAL DISEASE; PHYSICAL HEALTH PARAMETERS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHIATRIST; RECORDING; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; COOPERATIVE BEHAVIOR; HEALTH BEHAVIOR; HEALTH STATUS; HUMANS; HYPERPROLACTINEMIA; INTERDISCIPLINARY COMMUNICATION; LIFE STYLE; MASS SCREENING; MEDICAL HISTORY TAKING; PATIENT CARE TEAM; PHYSICAL EXAMINATION; SCHIZOPHRENIA;

EID: 77954167884     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(10)71706-5     Document Type: Article

References (31)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
2. Basson R., Rees P., Wang R.X., Montejo A.L., Incrocci L. Sexual Function in Chronic Illness. J Sexual Medicine 2010, 7:374-388.
3. Buckley P.F., Miller d.D., Singer B., Arena J., Stirewalt E.M. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005, 79:281-288.
4. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003, 166:391-399.
5. Citrome L., Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 2005, 19:102-109.
6. Correll C.U. From receptor pharmacology to improved outcomes: individualizing the selection, dosing and switching of antipsychotics. Eur Psychiatry 2010, 25:S12-21.
7. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007, 89:91-100.
8. De Hert M., Dekker J.M., Wood D., Kahl K.G., Moller H.J. Cardiovascular Disease and Diabetes in People with Severe Mental Illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
9. De Hert M., van Winkel R., Silic A., Van Eyck D., Peuskens B. Physical health management in psychiatric settings. Eur Psychiatry 2010, 25:S22-S28.
10. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C.H., Lambert M., Leucht S., et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008, 69:514-519.
11. Gibney J., Smith T.P., McKenna T.J. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005, 62:633-643.
12. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):E1-E40.
13. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
14. Haupt D.W., Rosenblatt L.C., Kim E., Baker R.A., Whitehead R., Newcomer J.W. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009, 166:345-353.
15. Heald A. Physical health in schizophrenia: a challenge for antipsychotic therapy. Eur Psychiatry 2010, 25:S6-S11.
16. Hoschl C. Importance of physical health in patients with schizophrenia. Eur Psychiatry 2010, 25-S1-2.
17. Kinon B.J., Kaiser C.J., Ahmed S., Rotelli M.D., Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005, 25:255-258.
18. L'Italien G.J., Casey D.E., Kan H.J., Carson W.H., Marcus R.N. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007, 68:1510-1516.
19. Maguire G.A. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002, 63(Suppl. 4):56-62.
20. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003, 61:123-136.
21. Millar H. The development of a physical health screening clinic. Eur Psychiatry 2010, 25:S29-33.
22. Montejo A.L. The need for routine physical healthcare in schizophrenia. Eur Psychiatry 2010, 25-S3-5.
23. Montejo AL, Majadas S, Rico-Villademoros, F, Llorca G, De La Gándara J, Franco M, Martín-Carrasco M, Aguera L, Prieto N.; for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sexual Medicine 2010 [Epub ahead of print] PMID: 20214720.
24. Montejo A.L., Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQSALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008, 34:227-239.
25. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006, 86:15-22.
26. Newcomer J.W., Nasrallah H.A., Loebel A.D. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004, 24(5 Suppl. 1):S1-S6.
27. Peveler R.C., Branford D., Citrome L., Fitzgerald P., Harvey P.W., Holt R.I., et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008, 22:98-103.
28. Schiettecatte J., De Schepper J., Velkeniers B., Smitz J., Van Steirteghem A. Rapid detection of macroprolactin in the form of prolactinimmunoglobulin G complexes by immunoprecipitation with anti-human IgG-agarose. Clin Chem Lab Med 2001, 39:1244-1248.
29. Straker D., Correll C.U., Kramer-Ginsberg E., Abdulhamid N., Koshy F., Rubens E., et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005, 162:1217-1221.
30. Turrone P., Kapur S., Seeman M.V., Flint A.J. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002, 159:133-135.
31. Weiden P.J., Simpson G.M., Potkin S.G., O'Sullivan R.L. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003, 64:580-588.